FDA issues Breakthrough Therapy designation for ribociclib for premenopausal women with HR /HER2- advanced breast cancer

Ribociclib has received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2CEO6XD
via IFTTT